The latest updates and news
May 07, 2025
Built on Elegen’s proprietary cell-free technology, ENFINIA IVT Ready DNA delivers both standard and very complex double-stranded linear templates up to 5.5 kb that additionally include encoded poly(A) tails of 70–130 adenosines, with turnaround in as few as 10 business days. Compared to plasmid DNA, the process achieves low tail polydispersity and avoids the common pitfalls of plasmid-derived templates—including genomic DNA contamination, endotoxins from bacteria and time-consuming cloning, linearization and purification steps.
SOURCE: Businesswire
April 4, 2025
The rising tide of genetic medicines is shifting the role of synthetic DNA in pharmaceutical development. This article explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
SOURCE: Drug Development & Delivery
MARCH 31, 2025
Strategic partnership marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb.
SOURCE: Business Wire
MARCH 18, 2025
Elegen has again been named among the world’s most innovative companies by Fast Co., ranked within the “Small but Mighty” category
SOURCE: Fast Company
MARCH 05, 2025
Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair.
SOURCE: Elegen News
FEB 27, 2025
The Pinnacle Awards celebrate companies and individuals who have demonstrated exceptional innovation, leadership, and impact in the healthcare industry. Elegen proudly announces being named the top Innovator in Biotech Solutions!
SOURCE: Pinnacle Awards
JAN 21. 2025
Biocompare looks at vaccine design, examining considerations from antibody characterization to complex delivery platforms, like LNPs, and use of AI prediction and design.
SOURCE: Biocompare
JAN 16, 2025
Researchers from the California Institute of Technology describe a new method that alternates between library synthesis/screening and machine learning (#ML) to optimize mutations and unlock a more efficient, effective, and faster DBTL cycle for protein engineering. Elegen’s ENFINIA DNA delivered sequence-perfect genes within a week to accelerate optimization cycles.
SOURCE: Nature Communications
JAN 15, 2025
Steven Roberts, PhD, Director, Scientific Collaborations within GSK Vaccine and Infectious Diseases External Research and Development, discusses what his team really looks for in Research and Development partnerships to create new verticals in vaccine and infectious disease therapeutics.
SOURCE: PODD – Partnership Opportunities in Drug Discovery
JAN 09, 2025
Elegen today announced the launch of ENFINIA™ Plasmid DNA, a faster, cost-effective solution for clonal synthesis of long and complex genes. ENFINIA Plasmid DNA provides access to high-complexity clonal genes up to 15 kb, NGS-verified and shipped globally from Elegen’s U.S. facilities in just 10 business days to slash lead times from months to weeks at an affordable price.
SOURCE: Elegen News
JAN 07, 2025
The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2024, including Elegen founder and CEO Matt Hill. This recognition highlights CEOs whose leadership has inspired their teams to push boundaries, fostering cultures of innovation that have led to transformative breakthroughs in medical devices, digital health, software, biotechnology, and beyond.
SOURCE: The Healthcare Technology Report
DEC 06, 2024
Synthesis of DNA via cell-free methods has many benefits versus fermentation. Advanced technologies, with higher-throughput and smaller footprints that replace fickle cells with more repeatable in vitro approaches, are likely the answer to the growing need to iterate fast in R&D and transition to clinical in a fraction of the time it takes today.
SOURCE: Biopharm International
NOV 24, 2024
DNA technologies were one of the focus areas of this year’s R&D 100 Awards, with winners showcasing advances in forensic analysis, synthetic DNA production, and sequencing accuracy. This article recaps four DNA and genomics advances recognized in the 2024 awards, among them Elegen’s ENFINIA DNA technology, which can achieve 20x higher accuracy in synthetic DNA production.
SOURCE: R&D World
NOV 20, 2024
The Healthcare Technology Report is pleased to announce its annual awards for The Top 100 Healthcare Technology Companies. This year’s awardees were selected based on a methodical review of nomination submissions as well as further in-depth research into each candidate’s products and solutions, corporate track record, management team caliber, and organizational depth, among other factors.
SOURCE: The Healthcare Technology Report
NOV 19, 2024
Elegen’s ENFINIA™ DNA has been named “DNA Synthesis Technology Of The Year” by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
SOURCE: Biotech Breakthrough Awards
OCT 24, 2024
Messenger RNA vaccines have shown their value for a broad range of therapeutic applications, ranging from cancer immunotherapy to infectious diseases. Additionally, vigorous efforts are now being devoted to the use of IVT mRNA technology for other uses such as cell therapy and gene editing. While these mRNA-based approaches show great promise as next-generation therapeutics, there are still many open questions about the effect of mRNA impurities that can occur during the IVT reactions.
SOURCE: Analytical Chemistry
OCT 04, 2024
Biocompare recently spoke with several companies, including Elegen, that have developed critical enabling technologies for drug discovery and development with synthetic biology, gaining valuable insight into its current achievements, what the future looks like, and key areas that need to be addressed for us to get there
SOURCE: Biocompare
AUG 08, 2024
The official 2024 R&D 100 Awards have been announced by R&D World, and Elegen’s ENFINIA DNA is a winner!
SOURCE: R&D World
AUG 01, 2024
A total of 141 Finalists for the 2024 R&D 100 Awards have been announced by R&D World. This renowned worldwide science and innovation competition, celebrating its 62nd year, received entries from 16 different countries and regions. Elegen’s ENFINIA DNA, next-generation gene synthesis manufactured entirely cell free, is among the finalists.
SOURCE: R&D World
JUL 18, 2024
This Genetic Engineering News eBook reviews advances in mRNA vaccine and therapy development, including next-generation gene synthesis via cell-free cloning.
SOURCE: Genetic Engineering News
JUL 02, 2024
Genetic Engineering News reviews several DNA manufacturing technologies that have emerged to give synthetic biology companies what they need to revolutionize the life sciences.
SOURCE: Genetic Engineering News
JUN 10, 2024
BizTech Outlook named Elegen among the Top Innovative Companies to Watch in 2024. Read this interview to learn why innovation is this company’s DNA.
SOURCE: BizTech Outlook
MAY 14, 2024
Elegen announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines; John Ballantyne, co-founder of Aldevron; and existing investors.
SOURCE: Elegen News
APR 29, 2024
The Keatinge-Clay lab at the University of Texas at Austin ordered de novo synthesis of a 14,713 bp plasmid containing a PKS gene cluster. Elegen’s rapid, full-length plasmid synthesis saved the lab weeks of assembly time and labor when compared to traditional approaches. With Elegen’s ability to synthesize regions of high complexity, labs are able to move projects with difficult complex sequences, including repetitive GC-rich regions, from the drawing board to the incubators in a matter of weeks.
SOURCE: Big4Bio
APR 15, 2024
In this episode of Big4Bio’s Company to Watch, Danny Levine interviews Matthew Hill, Ph.D., founder and CEO of Elegen, on the next big innovation in manufacturing DNA, which bypasses synthetic DNA bottlenecks to accelerate upstream and downstream workflows.
SOURCE: Big4Bio
APR 08, 2024
Randy Dyer, Vice President of Marketing, discusses the mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA for genetic medicine development and other biotechnology applications.
SOURCE: Big4Bio
MAR 20, 2024
Following successful, fully subscribed Early Access and Beta Programs, Elegen’s latest ENFINIA DNA enhancement provides access to very challenging sequences, including long repeats and STRs, GC-rich promoters, enhancers, terminators, ITRs, LTRs and homopolymers.
SOURCE: Elegen News
MAR 19, 2024
Elegen has been named among the world’s most innovative companies by Fast Co., ranked #2 in “Small but Mighty.”
SOURCE: Fast Company
MAR 06, 2024
Elegen has been named among the Top 25 Biotechnology Companies of 2024 by the Healthcare Technology Report.
SOURCE: The Healthcare Technology Report
FEB 06, 2024
Next-generation vaccines and therapies in development, including those based on DNA, RNA, and viral vectors, are all overwhelmingly manufactured using plasmid DNA (pDNA). The traditional method for the large-scale production of pDNA involves fermentation in E. coli strains, which is a laborious, time-consuming, and expensive process, making plasmid production a bottleneck and potential inhibitor of growing success for next-generation therapies. Cell-free routes to synthetic DNA may address the problem.
SOURCE: Pharmas Almanac
FEB 01, 2024
Cell and gene therapies (CGT) represent the cutting edge of biotherapeutics, using DNA and life itself as therapeutic agents. CGT process development requires the coordination of many parts, including cells, DNA constructs, and gene delivery vectors. As a key starting material, CGT development requires a constant flow of high-accuracy, long, and complex custom DNA. Elegen is addressing this synthesis bottleneck with its cell-free DNA synthesis process.
SOURCE: BioCompare
JAN 31, 2024
Exclusive Interview: Elegen CEO Matthew Hill on new collaboration with GSK.
SOURCE: SynBioBeta
JAN 27, 2024
In this episode of Life Science Success Don Davis interviews guest Matt Hill, founder and CEO of Elegen, a privately-held company based in the San Francisco Bay Area, committed to revolutionizing synthetic biology workflows with an innovative DNA writing technology.
SOURCE: Life Science Success Podcast
JAN 24, 2024
Elegen’s ability to produce NGS-verified linear DNA up to 7 kb within a week with error rates as low as 1:70,000 per bp (99.999% per base accuracy) could be an important marker as it tries to establish a leading position in a heated race to deliver what could be the next major medicinal breakthrough.
SOURCE: Genetic Engineering News
JAN 24, 2024
GSK has signed a collaboration & licensing agreement to leverage Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines & medicines.
SOURCE: Elegen News
JAN 10, 2024
Business Intelligence Group Announces the Winners of the 2024 BIG Innovation Awards
SOURCE: Business Intelligence Group
DEC 04, 2023
Recent innovations in DNA manufacturing are helping eliminate critical bottlenecks to bring new therapies to market faster than ever.
SOURCE: Technology Networks
OCT 31, 2023
Nature reviews the latest advancements in DNA synthesis and the key challenges the new players like Elegen are quickly overcoming.
SOURCE: Nature Biotechnology
OCT 03, 2023
Biocompare recently published on the challenges of scaling cell therapies. Part of this challenge starts UPSTREAM in determining the optimal DNA sequence for expansion–a time-consuming, resource-intensive process.
SOURCE: Biocompare
JUL 01, 2023
Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development.
SOURCE: Drug Discovery World Magazine
JUN 14, 2023
Podcast featuring Matt Hill – Founder & CEO of Elegen
SOURCE: BIOS Community
MAY 23, 2023
DNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time
SOURCE: Elegen News
MAY 16, 2023
Company focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.
SOURCE: Elegen News
APR 24, 2023
Guest author John Cumbers, CEO of SynBioBeta meets with Elegen Founder and CEO, Matthew Hill
SOURCE: Forbes
APR 20, 2023
Mendelspod Podcast Featuring Elegen CEO and Founder, Matthew Hill
SOURCE: Mendelspod
APR 12, 2023
Note: GenomeWeb Premium Subscription Required
SOURCE: GenomeWeb
MAR 21, 2023
New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market
SOURCE: Elegen News
FEB 09, 2023
The team at Elegen knows that when barriers to the fast, accurate, and low-cost synthesis of long DNA fall, biotechnology will be driven by the design-build-test-learn cycle
SOURCE: Genetic Engineering News
Subscribe to our latest news and product updates. (enter work email address only).
Elegen Corp
3565 Haven Ave, Suite 3
Menlo Park, CA 94025
© 2025 Elegen Corporation. All Rights Reserved.
